TG Therapeutics Inc
$ 34.56
2.28%
14 Apr - close price
- Market Cap 5,395,866,000 USD
- Current Price $ 34.56
- High / Low $ 34.68 / 33.72
- Stock P/E 12.20
- Book Value 4.52
- EPS 2.77
- Next Earning Report 2026-05-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 1.03 %
- 52 Week High 46.48
- 52 Week Low 25.28
About
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Analyst Target Price
$44.43
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-03 | 2025-08-08 | 2025-04-29 | 2025-02-26 | 2024-11-04 | 2024-08-06 | 2024-05-01 | 2024-02-28 | 2023-11-01 | 2023-08-01 | 2023-05-01 |
| Reported EPS | 0.14 | 2.43 | 0.17 | 0.03 | 0.15 | 0.02 | 0.04 | -0.07 | -0.1 | 0.73 | -0.34 | -0.28 |
| Estimated EPS | 0.3271 | 0.22 | 0.19 | 0.174 | 0.09 | 0.03 | -0.05 | -0.04 | -0.1 | 0.12 | -0.25 | -0.37 |
| Surprise | -0.1871 | 2.21 | -0.02 | -0.144 | 0.06 | -0.01 | 0.09 | -0.03 | 0 | 0.61 | -0.09 | 0.09 |
| Surprise Percentage | -57.1996% | 1004.5455% | -10.5263% | -82.7586% | 66.6667% | -33.3333% | 180% | -75% | 0% | 508.3333% | -36% | 24.3243% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.25 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TGTX
2026-04-12 22:24:00
This article provides a price-driven insight for Tg Therapeutics Inc. (NASDAQ: TGTX) for rule-based trading strategies. It highlights a strong near and mid-term sentiment but a weak long-term outlook with elevated downside risk. The analysis includes AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis for support and resistance levels.
2026-04-08 17:39:54
BofA Securities has reiterated its Sell rating on TG Therapeutics (TGTX.US) and maintained a target price of $15. This indicates a continued bearish outlook from BofA Securities on the company's stock performance.
2026-04-05 09:09:30
TG Therapeutics, Inc. (NASDAQ:TGTX) has received a "Moderate Buy" consensus recommendation from six research firms, with an average 12-month price target of $50.00. The company recently reported a Q3 EPS of $0.14, missing estimates, but revenue of $192.57 million was in line with expectations and up 78% year-over-year. Institutional investors hold approximately 58.58% of the stock.
2026-04-04 13:40:01
TG Therapeutics Inc (TGTX) is currently considered undervalued based on its forward P/S ratio of 4.71 compared to its five-year average of 24.66. Its fair price is estimated to be between $53.47 and $73.90, significantly higher than its current price of $33.53. The company also exhibits robust revenue growth of 78.00%, which supports its P/S ratio relative to competitor averages.
2026-04-02 20:39:44
The NASDAQ page for TG Therapeutics Inc. (TGTX) shows its current stock price at $33.00, down $0.58 (-1.73%). The article provides basic stock information, including a chart and a note that there is no available analyst rating or earnings information for the company. It also includes various promotional messages for trading tools and services.
2026-04-01 21:10:09
This article provides an analysis of Tg Therapeutics Inc. (NASDAQ: TGTX), highlighting strong near- and mid-term sentiment but a weak long-term outlook with elevated downside risk. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis for support and resistance levels. The report emphasizes the absence of clear long-term support signals, suggesting caution for long-term investors.
